SABS · SAB Biotherapeutics, Inc.
$3.88
+0.07 (+1.84%)
At close · Aug 26
Market Cap
$353.03M
Shares
90.99M
The company's filings as submitted to the SEC's EDGAR system — 10-K, 10-Q, 8-K, proxy statements and more — listed most recent first.
| Type | Filing Date | Period | Open |
|---|---|---|---|
| 10-Q | 2026-08-06 | 2026-06-30 | |
| 8-K | 2026-07-07 | — | |
| 8-K | 2026-06-18 | — | |
| 10-Q | 2026-05-12 | 2026-03-31 | |
| 8-K | 2026-05-04 | 2026-04-28 | |
| DEF 14A | 2026-04-30 | 2026-06-18 | |
| 8-K | 2026-04-22 | — | |
| Investor Event Transcript | 2026-03-31 | — | |
| Investor Event Transcript | 2026-03-31 | — | |
| 8-K | 2026-03-19 | 2026-03-17 | |
| 8-K | 2026-03-10 | — | |
| 10-K | 2026-03-09 | 2025-12-31 | |
| 8-K | 2026-01-12 | — | |
| 8-K | 2026-01-07 | 2026-01-05 | |
| 8-K | 2025-12-29 | — | |
| 10-Q | 2025-11-14 | 2025-09-30 | |
| 8-K | 2025-09-30 | — | |
| 8-K | 2025-09-26 | — | |
| DEF 14A | 2025-08-29 | 2025-09-26 | |
| 10-Q | 2025-08-07 | 2025-06-30 | |
| 8-K | 2025-07-21 | — | |
| 8-K | 2025-07-17 | — | |
| DEF 14A | 2025-06-02 | 2025-07-17 | |
| 10-Q | 2025-05-09 | 2025-03-31 | |
| 10-K | 2025-03-31 | 2024-12-31 | |
| 8-K | 2025-02-05 | 2025-01-30 | |
| 8-K | 2025-01-28 | — | |
| 10-Q | 2024-11-06 | 2024-09-30 | |
| 8-K | 2024-09-09 | — | |
| 10-Q | 2024-08-08 | 2024-06-30 | |
| 8-K | 2024-07-31 | 2024-07-26 | |
| 8-K | 2024-06-27 | — | |
| 8-K | 2024-05-31 | 2024-05-26 | |
| DEF 14A | 2024-05-30 | 2024-05-22 | |
| 8-K | 2024-05-21 | — | |
| 10-Q | 2024-05-20 | 2024-03-31 | |
| 8-K | 2024-05-08 | 2024-05-03 | |
| 8-K | 2024-04-15 | 2024-04-12 | |
| 8-K | 2024-03-29 | — | |
| 10-K | 2024-03-29 | 2023-12-31 | |
| 8-K | 2024-03-08 | 2024-03-05 | |
| 8-K | 2024-02-02 | 2024-01-30 | |
| 8-K | 2024-01-26 | — | |
| 8-K | 2024-01-25 | 2024-01-23 | |
| 8-K | 2024-01-19 | — | |
| 8-K | 2024-01-03 | 2024-01-02 | |
| DEF 14A | 2023-12-18 | — | |
| 8-K | 2023-11-29 | — | |
| 8-K | 2023-11-22 | — | |
| 8-K | 2023-11-20 | 2023-11-14 |
Showing 1–50 of 116 filings
Key facts
CIK
1833214
CUSIP
78397T202
13F (30d)
96 filings
90 filers
Visit website
Investor relations